暂无内容
随着通货膨胀的持续,基金押注杂货——巴伦周刊
随着通货膨胀继续给美国消费者带来压力,埃德·林是最早的主权财富基金之一,也是美国州级最大的基金之一,刚刚在杂货上下了大赌注。阿拉斯加永久音乐会
Barron's21:30 (美东)
尽管市场下滑,吉利德科学(GILD)仍在增长:这是你需要知道的
Yahoo Finance17:50 (美东)
减肥药物和药物治疗中的许多用例
Yahoo Finance17:32 (美东)
由于现金限制,Hepion结束了NASH药物的2期研究
Seeking Alpha17:10 (美东)
看看阿斯利康最近的不寻常期权活动
金融巨头对阿斯利康采取了明显的看跌举动。我们对阿斯利康(纳斯达克股票代码:AZN)期权历史的分析显示了12笔不寻常的交易。深入研究细节后,我们发现了16%的交易
Benzinga16:45 (美东)
快讯 | Leap Therapeutics 13G文件显示,截至2024年4月10日,吉利德科学公司报告称,截至2024年4月10日,该公司持有13.9%的股份
Moomoo 24/716:43 (美东)
bic mutney : buy more
Dafydd Green楼主 : Might test the theory and see if it works… The market moves in mysterious ways, Cardiff Oncology (CRDF) had great data out yesterday and slumped, never quite know how markets take this kind of news (e.g. maybe people are looking at the data and thinking “well it’s good but it’s not great”)
Dafydd Green楼主 : Eventually $Atara Biotherapeutics (ATRA.US)$ went up 2.08% but the worst was $EQRx (EQRX.US)$ going down 13.54%… Note to self - investigate why that would have been (strength of trial data? Competitive market for KRAS+ CRC? I.e. not so many people and actually quite a lot of drugs, and OS that’s not so special at 9months)
Evil_Monkey : You have to buy the rumor and sell the news. Once it hits the news, you should have already sold.